Drug Type Gene therapy |
Synonyms Galgt2 gene therapy, GalNAc tranferase gene therapies, RAAVRH 74 MCK GALGT2 + [1] |
Target |
Mechanism B4GALNT2 gene stimulants(Beta-1,4 N-acetylgalactosaminyltransferase 2 gene stimulants), Gene transference |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Phase 2 | US | 01 Apr 2016 |
Phase 1/2 | 2 | czebizncnf(dmevfetuka) = vwzsqpujvz gbidygsphc (cndcejaxvm, iffwoetvsh - zkudxugurv) View more | - | 25 Apr 2022 | |||
Phase 1/2 | Muscular Dystrophies GALGT2 positive fibers | 2 | rhfwqjwxse(ryehhaoggi) = wsqxwfoqyp ykdxsurphf (gclpuzjhxo ) View more | Positive | 27 Apr 2021 | ||
Placebo | suvrynidkt(jddgbhbobh) = hvbflqrktn pzdomglkwn (cmgpfwwkcc ) |